Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.

Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.

The object of the present invention is to provide a composition having a blood pressure-lowering effect and/or an anti-stress effect, wherein an active ingredient of a choline ester such as acetylcholine, and the like, can be easily administered to humans by the oral pathway.

Consequently, the object of the present invention is to provide a novel composition for oral ingestion having a blood pressure-lowering effect and a vasodilatory effect, wherein a choline ester such as acetylcholine, and the like, can be easily administered to humans by the oral pathway, and to provide food which is a useful supply source therefore.

A pharmaceutical composition or dietary supplement is described that is effective in the treatment of neuropathies and/or neuropathic pain, comprising, as the active ingredients, a combination of curcumin, N-acetyl-L-carnitine and alpha-lipoic acid.

A pharmaceutical composition or dietary supplement is described that is effective in the treatment of neuropathies and/or neuropathic pain, comprising, as the active ingredients, a combination of curcumin, N-acetyl-L-carnitine and alpha-lipoic acid.

A link between ApoE4 allele and sirtuins expression level is identified that is believed to be associated with elevated risk for the promotion of processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway in a mammal leading to elevated risk for Alzheimer's disease. Compounds are identified that upregulate sirtuins (e.g., SirT1) expression levels and appear to be useful in the treatment and/or prophylaxis of MCI and/or Alzheimer's disease.

Disclosed herein are compositions, formulations, methods, devices and kits for modulating the production of cerumen, the treatment of ceruminosis, and the treatment of ceruminosis associated diseases or conditions. In these methods, the otic compositions and formulations are administered locally to an individual afflicted with ceruminosis and/or ceruminosis associated diseases, through direct application of the otic compositions and formulations to the external ear canal.

Disclosed herein are compositions, formulations, methods, devices and kits for modulating the production of cerumen, the treatment of ceruminosis, and the treatment of ceruminosis associated diseases or conditions. In these methods, the otic compositions and formulations are administered locally to an individual afflicted with ceruminosis and/or ceruminosis associated diseases, through direct application of the otic compositions and formulations to the external ear canal.

This invention relates to a method for repairing and reconstructing a damaged or non-functional muscle, in particular to a method and a tool kit using in vitro primed motor endplate-expressing muscle progenitor cells (MPCs) to promote innervation of the damaged or non-functional muscle using an agent without any genetic manipulation. This method is particularly useful for repairing or reconstructing damaged or non-functional head and neck muscles, and urinary detrusor bladder muscle.

The present invention provides methods of preventing, treating, and/or reducing noise induced hearing loss and/or noise-induced inner ear trauma. The methods include the administration of glatiramer acetate or a derivative thereof and, optionally, at least one anti-oxidant.